ZVRA250117C5000
- 4.00
- 0.000.00%
Zevra Therapeutics Newsroom
Cantor Fitzgerald Initiates Zevra Therapeutics(ZVRA.US) With Buy Rating, Announces Target Price $25
Zevra Therapeutics (ZVRA) Receives a Buy From Cantor Fitzgerald
JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17
JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17
William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $20
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $25
Zevra Therapeutics: Strong Financials, Strategic FDA Approval, and Growth Prospects Drive Buy Rating
Zevra Therapeutics Is Maintained at Buy by Canaccord Genuity
Zevra Therapeutics Price Target Cut to $23.00/Share From $25.00 by Canaccord Genuity
Zevra Therapeutics Analyst Ratings
CCORF Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $23
Roth MKM Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $21
Zevra Therapeutics (ZVRA) Receives a Buy From Roth MKM
William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating
JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17
Zevra Therapeutics: Strong MIPLYFFA Launch and Strategic Investments Justify Buy Rating Despite OLPRUVA Challenges
JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17
JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17
William Blair Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating